Pipe|bio is the bioinformatics cloud for antibody / peptide screening & drug development. We enable scientists to analyze and manage massive amounts of DNA sequencing data themselves without the need for bioinformaticians or programmers.
PipeBio is a Y Combinator company in the Winter 2021 batch. Its directory entry describes it as: PipeBio is a SaaS bioinformatics platform to develop antibody drugs. The founders listed are Owen Bodley (Founder), Jannick Bendtsen (Founder) (Y Combinator directory entry, March 2, 2021).
Sell to companies like PipeBio? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2021-03-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns PipeBio.
Free to see. No signup.
More on PipeBio and the records around it.
Get an email when PipeBio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when PipeBio raises, hires or launches. No email unless you switch it on.
Watch PipeBio →Get the full cited report on PipeBio
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on PipeBio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Pipe|bio is the bioinformatics cloud for antibody / peptide screening & drug development. We enable scientists to analyze and manage massive amounts of DNA sequencing data themselves without the need for bioinformaticians or programmers. The software is highly visual and enables you to overlay and filter information from different sources across your organization; be it assay data, sequence data or other process metadata. Insights from past results can be used to guide new experiments and they get better as you upload more and more data. Team leads get oversight and these capabilities combined empower organizations to find better drugs, faster. We believe that science moves faster when scientists can curate and analyse their own data.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on PipeBio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PipeBio covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist PipeBioYou get an alert in MentionFox the next time this company shows up.
If you're behind PipeBio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for PipeBio. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-pipebio